This joint resolution uses the Congressional Review Act to disapprove the Bureau of Consumer Financial Protection’s rule that withdrew the agency’s 2024 Regulation F rule on deceptive and unfair collection of medical debt. The text declares the Bureau’s withdrawal (90 Fed.
Reg. 20084, May 12, 2025) to be without force or effect, which restores the regulatory status quo by leaving the original Regulation F medical‑debt provisions (89 Fed. Reg. 80715, Oct. 4, 2024) intact.
Why this matters: if enacted, regulated actors — primarily third‑party debt collectors, hospitals and health systems that outsource collections, and their compliance teams — would continue to be bound by the Regulation F medical‑debt requirements. The resolution also triggers the CRA’s downstream constraint: the Bureau would be barred from issuing a “substantially the same” rule in the future without explicit new authorization from Congress, sharply limiting the agency’s administrative flexibility on this topic.
At a Glance
What It Does
The joint resolution disapproves the CFPB rule that withdrew the agency’s 2024 Regulation F provisions addressing deceptive and unfair collection of medical debt and states that the withdrawal shall have no force or effect. It invokes chapter 8 of title 5, U.S.C. (the Congressional Review Act), so the agency would be blocked from reissuing a substantially similar rule without new statutory authorization.
Who It Affects
Primary affected parties are debt collectors subject to Regulation F, health care providers and third‑party collectors who implement collection practices, corporate compliance and legal teams preparing policies and disclosure forms, and consumer protection advocates. The CFPB’s rulemaking agenda and enforcement posture on medical‑debt practices would also be constrained.
Why It Matters
The measure would restore regulatory certainty for consumer‑facing protections created by the 2024 Regulation F medical‑debt provisions and create a legal barrier to administrative rollback of those protections. For compliance officers, it means ongoing obligations rather than a window to relax policies; for agencies, it means the CRA will limit regulatory workarounds.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The resolution is narrowly tailored: it does not change the text of Regulation F itself, nor does it rewrite substantive obligations. Instead, it exercises the Congressional Review Act to declare that the Bureau’s separate rule — the one that attempted to withdraw the medical‑debt portion of Regulation F — is disapproved and has no legal effect.
The practical outcome is that the medical‑debt provisions published in October 2024 remain the governing law for debt collectors.
Under the CRA, a successful disapproval does more than void the target rule. It carries an administrative consequence: an agency that has a rule disapproved may not issue a new rule that is substantially the same without an act of Congress authorizing it.
That means the Bureau cannot simply repackage the withdrawn withdrawal or relitigate the same policy in similar form by rulemaking alone; Congress would need to provide explicit new authority to change course.Operationally, regulated entities should read this resolution as preserving the compliance, disclosure, and conduct standards the October 2024 Regulation F rule established for medical‑debt collection. For enforcement, the CFPB retains the authority to pursue violations under that rule as written; states and private litigants that rely on the Bureau’s standards would also continue to point to those provisions.
The resolution does not itself create new private rights or penalties beyond what Regulation F provides; it only prevents the Bureau’s attempted removal of those standards.
The Five Things You Need to Know
The resolution disapproves the CFPB’s rule that withdrew the Regulation F medical‑debt provisions — targeting the withdrawal published at 90 Fed. Reg. 20084 (May 12, 2025).
It declares that the withdrawal “shall have no force or effect,” meaning the 2024 Regulation F provisions on deceptive and unfair medical‑debt collection (89 Fed. Reg. 80715 (Oct. 4, 2024)) remain operative.
The resolution is filed under the Congressional Review Act (chapter 8 of title 5, U.S.C.), which, if enacted, bars the CFPB from issuing a substantially similar rule in the future without explicit new authorization from Congress.
The measure does not amend Regulation F’s substantive text; its effect is procedural/legal — preserving existing obligations rather than changing substantive standards or enforcement penalties.
Because it is a joint resolution under the CRA, passage has the statutory effect of invalidating the targeted rule and constraining the agency’s subsequent rulemaking on the same subject.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Disapproval of the CFPB's withdrawal rule
This provision is the resolution’s core: it states that Congress disapproves the Bureau’s rule that withdrew the Regulation F medical‑debt rule. Practically, it is the language that, under the CRA, nullifies the specified agency action and makes that nullification the express will of Congress.
Identifies the specific rules and Federal Register entries targeted
The resolution names both the original Regulation F medical‑debt rule (89 Fed. Reg. 80715, Oct. 4, 2024) and the subsequent withdrawal entry (90 Fed. Reg. 20084, May 12, 2025). That specificity matters because CRA disapproval applies to the particular agency action cited; accurate citation limits ambiguity about what is being invalidated.
States the withdrawal 'shall have no force or effect'
This clause converts the resolution into an instrument that, if enacted, strips the withdrawal of legal effect. In practice that leaves the status of Regulation F’s medical‑debt provisions as they existed before the Bureau published the withdrawal. The provision also triggers the CRA’s downstream limitation on an agency’s ability to promulgate a substantially similar rule thereafter.
This bill is one of many.
Codify tracks hundreds of bills on Finance across all five countries.
Explore Finance in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers with medical debt — they retain the protections and disclosure limits embedded in the October 2024 Regulation F text, preserving guardrails against certain collection practices.
- Consumer‑advocacy groups — the resolution preserves a regulatory baseline they rely on for enforcement referrals, litigation strategy, and public advocacy.
- State attorneys general and state regulators — they keep a federal standard that supports parallel enforcement actions and state litigation against unfair medical‑debt collection practices.
Who Bears the Cost
- Third‑party debt collectors and collection law firms — they must continue to comply with the Regulation F medical‑debt rules, which may restrict collection tactics and increase compliance program costs.
- Health systems and small providers that outsource collections — continued regulatory constraints can raise administrative and operational costs, and require tighter vendor oversight.
- The Bureau of Consumer Financial Protection — the CRA’s disapproval removes a regulatory option and narrows the Bureau’s ability to change course administratively, potentially forcing more resource‑intensive alternatives (e.g., litigation or fresh rulemaking with congressional input).
Key Issues
The Core Tension
The central dilemma is between preserving consumer protections by using the CRA’s categorical remedy and preserving administrative flexibility: the resolution stops a rollback and protects consumers, but it does so by erecting a broad procedural barrier that limits the agency’s ability to revise rules through the administrative process — forcing policy disputes into Congress or litigation rather than rulemaking.
The resolution uses the blunt instrument of the Congressional Review Act, which resolves a discrete administrative action but can raise knotty implementation questions. One practical question is how the disapproval interacts with actions taken while the withdrawal was in effect — collections practices adopted, guidance issued, or enforcement decisions made during the interim period — because the resolution nullifies the withdrawal going forward but typically does not retroactively unwind administrative or private conduct taken in reliance on the now‑disapproved action.
That creates potential litigation and compliance uncertainty for conduct that occurred in the ambiguous interval.
Another tension is the CRA’s prohibition on issuing a substantially similar rule. The statute leaves substantial room for dispute over what counts as “substantially the same.” Agencies can try to redesign a rule’s form or rely on different legal rationale to achieve similar outcomes, which invites litigation over whether the new rule is impermissibly similar.
Finally, the resolution preserves regulatory text without addressing underlying policy trade‑offs or statutory constraints that prompted the withdrawal; if Congress wants different substantive law, it must legislate, but the resolution alone locks the agency into an operational position that some stakeholders may view as untenable.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.